Skip to Main Content

Paper Details

A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors.
NPJ Precis Oncol
35
2021
DLL3, DLL3-expressing tumors, Delta-like protein 3, MTC, NEC, NECs, NET, Patients, Rova-T at, Rovalpituzumab, Rovalpituzumab tesirine, advanced solid tumors, anemia, aspartate, aspartate aminotransferase, delta, delta-like 3, gastroenteropancreatic NEC, glioblastoma, large-cell NEC, medullary thyroid cancer, melanoma, neuroendocrine carcinomas, neuroendocrine prostate cancer, neuroendocrine tumors, patients, rovalpituzumab tesirine, solid tumors, thrombocytopenia
Author NameAffiliation
Himisha BeltranDana-Farber Cancer Institute
Himisha BeltranDana-Farber Cancer Institute
Saiama N WaqarWashington University School of Medicine
Alan H BryceMayo Clinic
Scott T Tagawa
Rahul AggarwalUCSF Helen Diller Family Comprehensive Cancer Center
  • 1 - 6

Datasets

Release 1.2